- 26 сентября, 00:43
- Zacks Investment Research
Monday, September 25, 2017
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Mondelez (MDLZ), Colgate-Palmolive (CL) and Stryker (SYK). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Mondelez's shares have lost +10.8% in the last three months, compared with the -7.6% dip of the Zacks Food Preparation industry. However, the Zacks analyst likes Mondelez’s attractive portfolio of iconic brands, commanding presence in impulsive categories and fast-growing emerging markets. Mondelez’s margins have remained constantly strong backed by cost savings and productivity gains.
The company has a mostly positive record of earnings surprises in recent quarters. However, Mondelez’s volumes have been hurt since 2014 by the elasticity impact from higher pricing and category weakness because of soft consumer demand. Moreover, with a significant portion of its sales coming from international markets, currency is a significant top-line headwind.
Shares of Buy-rated Colgate-Palmolive are up +8.8% in the year-to-date period, outperforming the Zacks Consumer Staples sector, which has gained +8.6% over the same period. The Zacks analyst likes the progress made on its 2012 Restructuring Program and expects additional opportunities identified under the program to help reach the higher end of its previously stated cost and savings view.
Moreover, the company has been infamous among investors with its meet or beat earnings track record. However, the company’s sales missed expectations for the fifth straight quarter in second-quarter due to continued softness in North America and challenges in Asia-Pacific. Further, the company lagged sales estimates in 16 out of the trailing 17 quarters.
Nevertheless, the company remains focused on four fundamentals to boost profits including, increased spending on advertisements; innovation across portfolio; higher spends on e-commerce business and aggressively maximizing productivity. Also, its disciplined capital strategy bodes well. Estimates have been stable lately.
Stryker’s shares have gained +21.2% over the last year, outperforming the Zacks Medical Products industry, which has increased +8.4% over the same period. Stryker announced the voluntary product recall of the Oral Care lineup recently. The recall is likely to adversely impact the company’s sales and operating income. Stryker exited the second quarter on a solid note, beating the Zacks Consensus Estimate on both counts. Solid performance in the MAKO platform drove revenues.
Upbeat guidance for the full year instills investor confidence on the stock. Stryker has a diversified product portfolio. Continued strong demand for hemorrhagic and ischemic stroke products and neuro-powered instruments boosted sales in the neurotechnology segment. However, volatility in foreign currency exchange is likely to impede revenue growth. Stryker also faces supply-side headwinds and has been grappling with issues in the spine business for long.
Other noteworthy reports we are featuring today include Nike (NKE), Fifth Third Bancorp (FITB) and Estee Lauder (EL).
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Per the Zacks analyst, Endo continues to benefit from robust performance of Xiaflex but both the generics and branded segment are facing competitive pressure which should impact the top-line.
Per the Zacks analyst, Public Service Enterprise is expanding its renewable assets that will drive growth. Yet, inability to comply with laws and regulations could affect its earnings adversely.
The Zacks analyst thinks that Sargent buyout and sturdy aerospace and industrial markets sales will boost RBC Bearings results.
Per the Zacks analyst Aflac's strong U.S. business has aided top line growth but its large exposure to Japan exposes it to foreign exchange volatility.
Per Zacks analyst, Diageo has been benefitting from booming sales of premium alcohol brands, growth in emerging markets and strategic acquisitions.
Per the Zacks analyst, Huntington Ingalls maintains stable liquidity. Solid capital resources fund its operations which allow it to constantly generate improved cash flow from operations.
Per Zacks analyst, Estee Lauder has been growing on the back of rising demand for beauty products, particularly in the luxury arena and in makeup.
The Zacks analyst is bullish about Rogers Communications' wireless growth from the roll out of lower block spectrum and the offering of Internet of Things as a service to business enterprises.
Per the Zacks analyst, Fifth Third's Project North Star initiatives are expected to enhance revenue growth, lower expenses and optimize its balance sheet position by the end of 2019.
Per the Zacks analyst, Square is benefiting from its expanding product portfolio and comprehensive commerce ecosystem. The company has applied for a banking license, which is a key catalyst.
PPG Industries faces currency headwinds and raw material cost pressure which may weigh on its earnings in Q3, per the Zacks analyst. Some of its end-markets including marine also remain sluggish.
Per the Zacks analyst, Nike's lackluster sales in North America are due to dull product assortments, increased promotions and intensified competition. This is likely to hurt the segment's future sales
Per the Zacks analyst, Synchrony Financial is affected by the company's rising level of expenses. Moreover increasing allowance for loan losses and rising fraud related losses are other worries.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Stryker Corporation (SYK): Free Stock Analysis Report
Nike, Inc. (NKE): Free Stock Analysis Report
Mondelez International, Inc. (MDLZ): Free Stock Analysis Report
Fifth Third Bancorp (FITB): Free Stock Analysis Report
Estee Lauder Companies, Inc. (The) (EL): Free Stock Analysis Report
Colgate-Palmolive Company (CL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research